iPath Goldman Sachs Barclays Bank PLC iPath Exchange Traded Notes Linked to the CBOE S&P 500 BuyWrite Index Structured Product (BWV): Price and Financial Metrics ETF
BWV Price/Volume Stats - 7 Best ETFs for the NEXT Bull Market
| Current price | $0.18 | 52-week high | $1.95 |
| Prev. close | $0.19 | 52-week low | $0.18 |
| Day low | $0.18 | Volume | 534,200 |
| Day high | $0.20 | Avg. volume | 795,235 |
| 50-day MA | $0.32 | Dividend yield | N/A |
| 200-day MA | $0.79 |
BWV Stock Price Chart Interactive Chart >
iPath Goldman Sachs Barclays Bank PLC iPath Exchange Traded Notes Linked to the CBOE S&P 500 BuyWrite Index Structured Product (BWV) ETF Bio
The investment objective of the iPath CBOE S&P 500 BuyWrite ETN is to provide investors with exposure to the CBOE S&P 500 BuyWrite Index. The Index is designed to measure the total rate of return on a hypothetical "buy-write”, or "covered call", strategy on the S&P 500® Index. This strategy consists of a hypothetical portfolio consisting of a "long” position indexed to the S&P 500 Index and the sale of a succession of a one-month, at-the-money S&P 500® call options that are listed on the Chicago Board Options Exchange.
BWV ETF Info
| Issuer | |
| Expense Ratio | % |
| Asset Class | |
| Sector | Large Cap Blend ETFs |
| Assets Under Management (AUM) | N/A |
| Net Asset Value (NAV) | $0.00 |
| Options? | No |
| Total Holdings | N/A |
BWV Top Holdings
| Symbol | Company | % of Total |
Latest BWV News From Around the Web
Below are the latest news stories about ONCONETIX INC that investors may wish to consider to help them evaluate BWV as an investment opportunity.
Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to ShareholdersCINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer, Dr. Neil Campbell. To Our Valued Shareholders, As 2023 draws to a close, I am eager to share with you the significant strides Onconetix, Inc. (formerly Blue Water Biotech, Inc.) has made in our journey towards becoming a leader in oncology. This past quarter has been transformative, marked by strategi |
Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™Transaction strengthens commercial business with addition of diagnostics product and initial focus on prostate cancerCINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology company (the “Transaction”), and introduced a new name for the combined Company: Onconetix, Inc. The Transaction reflects a transformation of the business to one focused on |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayPre-market stock movers are a hot topic on Thursday and we're checking out all of the biggest ones worth watching this morning! |
Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology CompanyTransaction will Advance Company’s Shift in Business Strategy Aligned with Life Sciences Industry Expertise of New Leadership TeamCINCINNATI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”), today announced the execution of a non-binding term sheet regarding the acquisition of a private commercial stage oncology biotechnology company (the “Proposed Transaction”). This latest announcement is part of the Company’s new business strategy focusing on |
Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)CINCINNATI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced that it has received a letter from the Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the Nasdaq Stock Market, LLC Listing Rule 5250(c)(1) (the "Rule"). The Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (SEC). On October 20, 2023, BWB filed its Fo |
BWV Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | -69.13% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |